p53 is an established tumor suppressor that can activate the transcription of multiple target genes. Recent evidence suggests that p53 may contribute to the regulation of cell invasion and migration. In this study, we show that the forkhead box transcription factor FOXF1 is a novel target of the p53 family because FOXF1 is upregulated by p53, TAp73 and TAp63. We show that FOXF1 is induced upon DNA damage in a p53-dependent manner. Furthermore, we identified a response element located within the FOXF1 gene that is responsive to wild-type p53, TAp73b and TAp63g. The ectopic expression of FOXF1 inhibited cancer cell invasion and migration, whereas the inactivation of FOXF1 stimulated cell invasion and migration. We also show that FOXF1 regulates the transcriptional activity of E-cadherin (CDH1) by acting on its FOXF1 consensus binding site located upstream of the E-cadherin gene. Collectively, our results show that FOXF1 is a p53 family target gene, and our data suggest that FOXF1 and p53 form a portion of a regulatory transcriptional network that appears to have an important role in cancer cell invasion and migration.
INTRODUCTION
p53 is a tumor suppressor gene that is frequently mutated in multiple human cancers. In response to inappropriate growth signals and various types of cellular stress, p53 becomes activated and suppresses malignant transformation by inducing cell cycle arrest, apoptosis, DNA repair and senescence through the transactivation of its target genes. [1] [2] [3] [4] Therefore, the identification of new p53 target genes and p53-binding sites contributes to our understanding of how p53 exerts its tumor-suppressing effects under different cellular stresses. Interestingly, p53 has been shown to regulate the expression of anti-metastatic genes such as Maspin, 5 Cyclin G2, 6 Sharp-1, 7 Rad 8 and MET. p73 and p63 are two members of the p53 family that share a high degree of structural homology with p53; they are particularly similar in their DNA-binding domains. [10] [11] [12] [13] Owing to their sequence similarity to p53, p73 and p63 possess many p53-like functions such as the ability to induce cell cycle arrest, apoptosis, senescence and differentiation. Current data also suggest that p73 and p63 are primarily involved in normal development and differentiation. [14] [15] [16] Different isoforms have been identified for each of the p53 family proteins, which are produced as a result of multiple promoters or alternative splicing processes. As a result of differential promoter usage, p73 and p63 are expressed as functionally different isoforms. One group (TAp73 and TAp63) contains a transactivation domain at the N-terminal end, which can bind to p53-responsive elements and transactivate p53 target genes. In contrast, the transactivation domains of the other p63 and p73 isotypes (DN isoforms) are truncated but retain transactivation activity. As the DN isoforms are thought to have a role in blocking the transactivation of p53 family target genes and their respective TA isoforms, the DN isoforms are considered to be dominant-negative. The dominant-negative DN isoforms of p63 and p73 are overexpressed in several cancer types. Additionally, alternative splicing at the 3 0 end of the p63/p73 transcript generates at least three isoforms (a, b and g) that are expressed on both TA and DN backbones. These isoforms transactivate target genes to varying degrees, which then have important roles in cellular functions. The full-length isoforms TAp73a and TAp63a possess a C-terminal region that is highly similar to the sterile alpha motif (SAM) domain, which is a proteinprotein interaction domain found in proteins involved in developmental regulation. The TAp73b and TAp63g isoforms are the most transcriptionally active isoforms to induce apoptosis, although the activity of each isoform in biological processes is still not completely understood. 16, 17 Therefore, the TA isoforms may generally be expected to have a role in tumor suppression, whereas increased expression of the DN isoforms might be oncogenic. At least 30% of head and neck squamous cell carcinomas harbor mutations in genes that regulate squamous differentiation, such as p63. 18 Collectively, these data suggest that p73 and p63 may represent viable therapeutic targets in many cancer patients. Recently, researchers have employed a smallmolecule strategy aimed at stimulating TAp73 or TAp63 to trigger p53-like transcriptional responses in p53-deficient tumor cells.
RESULTS
The p53 family upregulates FOXF1 mRNA and protein expression levels To express the human p53 family genes, we generated the replication-deficient recombinant adenoviral vectors Ad-p53, Adp73a, Ad-73b, Ad-63g and Ad-63a for the p53, TAp73a, TAp73b, TAp63g and TAp63a genes, respectively. Upon infection with each adenoviral construct, we observed a dramatic increase in the expression of each appropriate p53 family member protein (for example, see Figure 1b ). To identify the specific targets regulated by the p53 family proteins, we performed an Affymetrix GeneChip analysis and then compared expression patterns between the human osteosarcoma cell line Saos-2 that was transfected with Ad-p53 or Ad-p63g. The microarray data were deposited into the NCBI Gene Expression Omnibus database (GEO; www.ncbi.nlm.-nih.gov/geo) and are accessible through the GEO series accession number GSE13504. We validated a strong induction of several known targets of p53 family members such as p21, PIG3, MDM2 JAG1 and AQP3 in this approach (please see GSE13504). We also found several genes whose expression level was altered in p53-and TAp63g-infected cells. One of such genes, FOXF1, was highly induced both by p53 and TAp63g. Based upon a microarray gene expression study, FOXF1 was significantly induced by p53 and TAp63g (49-and 137-fold, respectively, compared with control lacZ-expressing cells). In the present study, we focused on the FOXF1 gene for further analysis because previous reports included findings that expression of FOXF1 mRNA was frequently downregulated in primary cancers of the breast, colon and prostate. [21] [22] [23] We also hypothesized that FOXF1 may be one of the mediators downstream of p53 family to inhibit carcinogenesis.
The results from the microarray were confirmed by real-time RT-PCR with three human cancer cell lines, Saos-2, H1299 and DLD1. As shown in Figure 1a , FOXF1 mRNA expression was clearly induced by p53, TAp73a, TAp73b and TAp63g in all of the tested cell lines. These data were further confirmed by northern blot analysis on the human cancer cell lines Saos-2, U373, SW480, H1299, DLD1, LoVo and RKO (Supplementary Figure S1) . In the majority of the tested cell lines, the strongest FOXF1 induction was observed following TAp63g overexpression. In contrast, FOXF1 mRNA was not or little induced by TAp63a, which has been reported to be less potent in transcriptional activity than TAp63g, 24 in any of the tested cell lines. As a positive control, we performed a northern blot analysis with the known p53 target gene p21 (Supplementary Figure S1) . [25] [26] [27] To determine whether the increased FOXF1 mRNA was accompanied by increased protein expression, the FOXF1 protein level was examined by an immunoblotting assay. The total cellular FOXF1 protein level was increased in the p53-, p73-and p63-transfected cells (Figure 1b) , which is consistent with the real-time RT-PCR and northern blot analysis.
Endogenous p53 upregulates FOXF1 We next examined whether activated endogenous p53 can induce FOXF1. To this end, HCT116 cells expressing wild-type p53 (HCT116-p53( þ / þ )) and isogenic mutant cells lacking p53 (HCT116-p53( À / À )) were treated with Nutlin-3, an Mdm2 inhibitor. As Mdm2 negatively regulates p53, Mdm2 inhibition by Nutlin-3 leads to p53 activation. Indeed, treatment of HCT116-p53( þ / þ ) cells with Nutlin-3 resulted in the upregulation of p53 and its target p21, which was accompanied by an increase in FOXF1 mRNA and protein expression (Figures 2a and b) . However, increased FOXF1 expression was not observed in HCT116-p53 ( À / À ) cells following Nutlin-3 treatment. Similarly, when we examined FOXF1 expression levels in various human gastric and breast cancer cell lines upon treatment with adriamycin (ADR), LacZ  p53  TAp73  TAp73  LacZ  p53   Saos-2  U373   LacZ   p53   TAp73   TAp73   TAp63   TAp63   TAp63   TAp63  TAp73  TAp73  TAp63  TAp63 950 5500 Figure 1 . FOXF1 mRNA and protein upregulation by p53 family members (a) Real-time RT-PCR analysis shows FOXF1 mRNA upregulation following adenovirus-mediated transfer of the p53 family genes into human cancer cell lines. The cells were infected with adenoviruses at an MOI of 25 (Saos-2 and H1299) or 100 (DLD1) and the cells were harvested 24 h after infection. Relative gene expression levels were quantified using the DDCt method and the results were normalized to the expression of the housekeeping gene GAPDH. The data are shown as the mean±standard errors of three independent experiments and were normalized to their respective controls as 1. (b) Upregulation of FOXF1 protein by p53 family members. Cells were infected with the indicated adenoviruses as described above and immunoblot analysis was performed using an anti-FOXF1 antibody.
p53-inducible FOXF1 inhibits cancer cell motility M Tamura et al increased FOXF1 expression was observed in a wild-type p53-dependent manner (Supplementary Figure S2) . Moreover, Foxf1 expression was induced in mouse and rat fibroblasts in a wild-type p53-dependent manner (Supplementary Figure S3) . These results indicate that FOXF1 is upregulated by activating endogenous p53 in human and rodent cells. DNp63 is the predominant isoform expressed in cells of epithelial origin and frequently overexpressed in cancers. 28, 29 As FOXF1 was highly induced by TAp63g, we then addressed whether DNp63 could regulate FOXF1. As shown in Supplementary Figure S4 Figure S5b) . These observations suggest an inhibitory role of DNp63 in FOXF1 transcription, which is opposite from TAp63g.
A p53-responsive element exists within the FOXF1 gene As transcription factors, the p53 family proteins bind to specific DNA sequences in target genes to activate gene expression. To determine whether FOXF1 is a direct target of transcriptional activation by the p53 family of transcription factors, we searched for a consensus p53-binding sequence within the genomic locus encoding the human FOXF1 protein. A single potential binding site (designated RE-FOXF1, Figure 3a) was found within the first intron of the FOXF1 gene. RE-FOXF1 consists of three copies of the 10-bp consensus p53-binding motif and is well conserved between mouse and rat; RE-FOXF1 is found at nearly identical positions within the mouse and rat FOXF1 genes (Figure 3b) . We next performed chromatin immunoprecipitation (ChIP) assays to verify the direct binding of the p53 family proteins to RE-FOXF1. In the ChIP assay, we utilized Saos-2 cells that were infected with a control adenovirus Ad-LacZ and adenoviruses expressing FLAGtagged p53 family genes (Figure 3c , left). Crosslinked chromatin complexes from these cells were immunoprecipitated with an anti-FLAG monoclonal antibody (mAb), from which we measured the abundance of candidate sequences by real-time PCR. The ChIP assay revealed that a DNA fragment containing the RE-FOXF1 sequence was reproducibly present in the immunoprecipitated complex containing the p53, TAp73a, TAp73b or TAp63g protein (Figure 3c , middle), indicating that p53 family proteins can bind to the RE-FOXF1 site in vivo. As a positive control for the ChIP assay, we found that p53 family members can bind to the MDM2 promoter (Figure 3c, right) .
To determine whether the RE-FOXF1 sequence confers p53 family-dependent transcriptional activity, we performed a heterologous promoter-reporter assay using a luciferase vector pGL3-RE-FOXF1, which was prepared by cloning the oligonucleotide corresponding to RE-FOXF1 upstream of a minimal promoter. Saos-2, H1299 and SW480 cells were transiently co-transfected with pGL3-RE-FOXF1 and a p53-, p73a-, p73b-, p63g-or p63a-expressing plasmid. Figure 3d shows an increase in luciferase activity from pGL3-RE-FOXF1 by each of the p53 family members when compared with the empty vector alone. In contrast, mutations introduced in the RE-FOXF1-mut construct (pGL3-RE-FOXF1-mut) abolished the ability of the p53 family members to transactivate luciferase expression, supporting the hypothesis that FOXF1 is a direct target of the p53 family members. Additionally, these results are consistent with the expression patterns of FOXF1 upon its induction with various p53 family proteins (Figure 1 ).
Mutant p53 negatively regulates FOXF1 expression
Previous studies have shown that the expression levels of several members of the FOX gene family are altered in a variety of cancers. 30, 31 Recently, the FOXF1 gene has been shown to be a target of epigenetic inactivation and the FOXF1 gene product has also been shown to possess tumor suppressor activity. 21 Here, using a complete collection of human cancer microarray data (Oncomine Database), 32 we found that FOXF1 is significantly underexpressed in cancer tissues in multiple microarray data sets (Supplementary Figure S6) . The relationship between the expression of FOXF1 and prognosis in cancer patients was examined using the PrognoScan database (http://gibk21.bio.kyutech.ac.jp/ PrognoScan/index.html). PrognoScan is a large collection of publicly available cancer microarray data sets with clinical annotation and a tool for assessing the biological relationship between gene expression and prognosis. 33 As shown in Supplementary Figure S7 , the downregulation of FOXF1 correlated with poor prognosis in certain cancers (lung, colorectal, skin and breast cancers). Importantly, no data set showed an association between FOXF1 overexpression and poor prognosis.
In order to examine the relationship between FOXF1 expression and p53 mutational status, Oncomine databases were also investigated. We found four published cancer microarray data sets, in which the p53 status and FOXF1 expression have been reported. In all these four data sets, patients with mutant p53 show lower expression of FOXF1 mRNA than patients with wild-type p53 (Supplementary Figure S8) , although this did not reach statistical significance. We then examined the FOXF1 levels following transfection of MCF7 cells (expressing wild-type p53) with vectors containing tumor-derived p53 mutants. As shown in Supplementary Figure S9 , compared with the vector control, some p53 mutants (R175H, R248Q, R248W, R249S, R273C, R273H and R282W) repressed FOXF1 protein expression. Additionally, we found a reduction of Relative gene expression levels were quantified using the DDCt method and the results were normalized to the expression of the GAPDH gene. The data are shown as the mean ± standard errors of three independent experiments and were normalized to their respective controls as 1.
p53-inducible FOXF1 inhibits cancer cell motility M Tamura et al siRNA vector when compared with cells expressing a control siRNA (Supplementary Figure S10a) . We also determined short-time cell proliferation by cell counting. In contrast to the colony-formation assays, no dramatic difference in proliferation between the FOXF1-knockdown cells and the control cells was observed, suggesting that FOXF1 has a limited effect on cell proliferation (Supplementary Figure S10b) . We then sought to determine whether FOXF1 regulates cell invasion and migration. Transwell assays revealed a significant increase in the invasion and migration of FOXF1-knockdown HCT116 cells when compared with the control cells (Figures 4a and b) . Similar patterns were observed in the SAS oral cancer cell line (Supplementary Figure S11) . Additionally, FOXF1-knockdown HCT116 cells exhibited a fibroblastic, spindle-shaped morphology, whereas control cells retained a tightly packed cuboidal epithelial-like morphology ( Supplementary Fig. S12 ).
Overexpression of FOXF1 inhibits cancer cell invasion and migration We transfected a FOXF1 expression vector into a Ca9-22 oral cancer cell line and a DLD1 colorectal cancer cell line, which are cell lines that express low levels of endogenous FOXF1. Upon subjecting these cells to invasion and migration assays, we showed that forced FOXF1 expression significantly reduces the invasion and migration capabilities of these cancer cells ( Figure 5 ). These results suggest that p53-inducible FOXF1 regulates cancer cell invasion and migration.
Regulation of E-cadherin transcription by FOXF1 As a transcription factor, FOXF1 binds to the specific DNA sequence RTAAAYA 34 found within its target gene and activates gene expression. We identified a potential FOXF1-binding site upstream of the CDH1 gene, which encodes E-cadherin and is involved in adhesion and normal epithelium maintenance. The candidate FOXF1-binding sequence was identified at nucleotide position À 3547, where þ 1 represents the transcription start site; the sequence of the binding site is ATAAATAAATA. As shown in Figure 6a , the silencing of FOXF1 in HCT116 cells inhibited E-cadherin protein expression relative to the parental cells and mock-transfected cells. FOXF1 siRNA did not alter the expression of E-cadherin repressors ZEB1 and ZEB2. We found that E-cadherin mRNA is expressed at lower levels in FOXF1-knockdown HCT116 cells than in control cells (Figure 6a . In vivo recruitment of p53 family proteins to the RE-FOXF1 site. Crosslinked chromatin was extracted from Saos-2 cells following infection with AdLacZ, Ad-p53, Ad-p73a, Ad-p73b, Ad-p63g or Ad-p63a, and the cell lysates were then immunoprecipitated with an anti-FLAG antibody. Realtime PCR amplifications were performed in triplicate for each precipitation with primers surrounding each site. The data were normalized to the signal from input DNA (right, means±s.e.). (d) The RE-FOXF1 sequence is responsive to p53 family members. Cells were transiently transfected with the pGL3-promoter vector containing RE-FOXF1 (pGL3-RE-FOXF1) or its mutant (pGL3-RE-FOXF1-mut) along with the transfection control plasmid expressing Renilla luciferase (phRG-TK). The cells were co-transfected with a control pCMV-Tag2 vector or a vector that expresses the p53 family members 24 h prior to performing the luciferase assay. Luciferase activity was measured using the dualluciferase reporter assay system using Renilla luciferase activity as an internal control. All of the experiments were performed in quadruplicate, and the mean and standard deviation are indicated by the bars.
p53-inducible FOXF1 inhibits cancer cell motility M Tamura et al regulates E-cadherin expression at the transcriptional level. Furthermore, the knockdown of FOXF1 led to significantly reduced E-cadherin mRNA levels in HEK293 cells (Figure 6b ). Subsequently, we performed ChIP assays to determine whether FOXF1 protein could bind to the candidate site in the E-cadherin gene in vivo. H1299 cells were transfected with a control and a Halo-tagged FOXF1 expression vector. Crosslinked chromatin complexes from these cells were immunoprecipitated with an anti-Halo Tag polyclonal antibody and the abundance of candidate sequences within the immunoprecipitated complexes was determined by PCR amplification. A FOXF1-binding site in the GH2 gene, 35 a known FOXF1 target, was used as a positive control. Additionally, a region within the GAPDH gene's promoter was amplified as a control for nonspecific binding (data not shown). As shown in Figure 6c , we observed a marked enrichment for a fragment containing the potential FOXF1-binding site (left panel). We designated this binding sequence RE-CDH1 for the response element in the CDH1 gene.
To determine whether the RE-CDH1 sequence that confers transcriptional activity is FOXF1-dependent, we performed a heterologous promoter-reporter assay using the luciferase vector pGL3-RE-CDH1, which was prepared by cloning the oligonucleotide corresponding to RE-CDH1 upstream of a minimal promoter. A negative control reporter plasmid pGL3-RE-CDH1-mut was constructed by altering potentially critical nucleotides within RE-CDH1 (see Materials and methods). FOXF1 siRNA downregulated the luciferase activity from pGL3-RE-CDH1 in HCT116 cells (Figure 6d) . Conversely, Figure 6e shows an induction of luciferase activity from pGL3-RE-CDH1 in HEK293 and H1299 cells following FOXF1 overexpression relative to cells transfected with an empty Figure  S13 ). Taken together, our results suggest that RE-CDH1 is a functional FOXF1-responsive element.
p53 family members activate E-cadherin transcription by upregulating FOXF1 expression We also found that luciferase activity from pGL3-RE-CDH1 in Saos-2 and H1299 cells is induced by p53 or TAp63g when compared with cells transfected with an empty vector (Figure 7a ). Additionally, E-cadherin mRNA was clearly induced by p53 and TAp63g in both cell lines (Figure 7b ). Next, we determined the impact of FOXF1 on E-cadherin expression mediated by p53 family members in H1299 cells, which represent the mesenchymal phenotype with low expression of E-cadherin. As shown in Figure 7c , FOXF1 siRNA partially blocked p53-and TAp63g-mediated E-cadherin induction at the protein level. In contrast, we observed the activation of endogenous PIG3, a known p53 target, by p53 family members in both control and FOXF1 RNAi-silenced cells. Taken together, these observations indicate that p53 family members regulate E-cadherin expression, at least in part, through the regulation of FOXF1. -cont) . The E-cadherin protein level was quantified by using the ImageJ software program after normalizing to actin levels and is presented as the foldchange. Right panel, FOXF1, E-cadherin and ZEB1 mRNA levels were assayed by real-time PCR. (b) Inhibition of FOXF1 expression by siRNA results in the reduction of E-cadherin mRNA expression. HEK293 cells were transfected with FOXF1 siRNA (si-FOXF1) or control siRNA (si-cont) every 24 h for 3 consecutive days using Oligofectamine. Twenty-four hours after the final transfection, the FOXF1, E-cadherin and ZEB1 mRNA levels were assayed by real-time PCR. (c) FOXF1 protein binds to the RE-CDH1 site in vivo. Crosslinked chromatin was extracted from H1299 cells following transfection with an empty vector or a FOXF1 expression vector and the lysates were then immunoprecipitated using an antiHalo antibody. In vivo recruitment of FOXF1 proteins to the RE-CDH1 site is shown by ChIP analysis (left). A binding site for the FOXF1 protein in the GH2 gene (RE-GH2) was used as a positive control (right). Reactions were performed in triplicate for each sample, and results were compared with total input DNA as the reference using the 2 -DDCT calculation method. (d) The RE-CDH1 sequence is critical for the transcriptional regulation of the CDH1 gene by endogenous FOXF1. Control and FOXF1-silenced HCT116 cells were co-transfected with the pGL3-promoter vector containing RE-CDH1 (pGL3-RE-CDH1) or a mutant derivative (pGL3-RE-CDH1-mut) together with the transfection control plasmid expressing Renilla luciferase, phRG-TK. Twenty-four hours after the transfection, the cells were subjected to a dual-luciferase assay. The data are expressed as the amount of Firefly luciferase activity relative to the Renilla luciferase control for each sample. The experiments were performed in triplicate and the standard deviation is indicated. Luciferase activity in the control HCT116 cells was set to 1. (e) The RE-CDH1 sequence is responsive to FOXF1. HEK293 and H1299 cells were transiently transfected with pGL3-RE-CDH1, pGL3-RE-CDH1-mut or an empty pGL3-promoter vector (pGL3-pro) along with phRG-TK. The cells were co-transfected with a control pFN21A vector or a vector that expresses FOXF1 24 h prior to performing the luciferase assay. Luciferase activity was measured using the dual-luciferase reporter assay system using Renilla luciferase activity as an internal control. All of the experiments were performed in triplicate, and the mean and standard deviation are indicated by the bars and brackets, respectively. 
DISCUSSION
Recent findings have provided evidence suggesting that the p53 family has broader roles in tumor suppression than previously expected. Interestingly, some studies have suggested that p53 may also contribute to the regulation of cell invasion and migration. We have recently found that the secreted protein HDGF is a transcriptional target repressed by p53 family members, and p53 regulates cancer cell growth and invasion in part via 36 Previous reports showed that p63 also functions as a regulator of cell migration and adhesion. [37] [38] [39] [40] [41] [42] [43] For example, TAp63 has an important role in tumor and metastasis suppression through the coordinate transcriptional regulation of Dicer and miR-130b. 44 Additionally, mutant p53 forms a complex with p63 to antagonize its cell migration-inhibitory function. 45 TAp73 is also found to maintain mammary epithelial cell polarity by suppressing epithelial-mesenchymal transition (EMT). 46 Although it is not yet possible to attribute an entire function of the p53 family to any one of its target genes, we propose that FOXF1 is a mediator of the p53 family in the regulation of cancer cell invasion and migration.
The present study shows that the FOXF1 protein binds to the FOXF1 consensus site upstream of the CDH1 gene and regulates E-cadherin expression at the transcriptional level. E-cadherin maintains cell polarity and normal epithelial structure. 47, 48 The reduction of E-cadherin increases cell motility and promotes cancer cell invasion. 49, 50 The downregulation of E-cadherin in tumors occurs due to genetic mutations, promoter hypermethylation or transcription factor dysfunction. Specifically, transcriptional repression is regarded as a fundamental mechanism of E-cadherin silencing during tumor progression. Several transcriptional repressors have been identified, such as members of the Snail, zinc finger E-box binding (ZEB) and basic helix-loophelix families. [51] [52] [53] Here, we demonstrate that the transcription factor FOXF1 can transactivate the CDH1 gene, which suggests that the p53 family has a role in the inhibition of cancer progression through the FOXF1/E-cadherin pathway. Recently, studies have shown that knockdown of endogenous p53 in ovarian cancer cells induces DNMT1 expression and leads to increased E-cadherin promoter methylation. 54 Moreover, p53 family members have been shown to transactivate miR-200c, which helps promote epithelial identity by directly targeting ZEB1/2, two EMT-related proteins responsible for repressing E-cadherin. 55 As neither FOXF1 siRNA nor the ectopic expression of FOXF1 altered ZEB expression (Figure 6a and data not shown), p53 may regulate E-cadherin expression through multiple mechanisms.
Overall, our demonstration that FOXF1 is a p53 target provides additional insight into p53-mediated tumor suppression. FOXF1 siRNA counteracts the effects of expressing p53 family members because FOXF1 downregulation reduced the level of the epithelial cell marker E-cadherin, which is otherwise increased by p53 or TAp63g expression (Figure 7c) . Therefore, the inhibition of FOXF1 induction by p53 inactivation and the subsequent failure of FOXF1-dependent downstream signaling events may confer a survival advantage to tumor-prone cells. In support of this view, FOXF1 expression has been shown to be downregulated in various tumor types. For instance, FOXF1 is silenced by DNA methylation in breast cancers, 21 suggesting that the loss of FOXF1 function may be an epigenetic event that promotes tumor progression. Recently, Lo et al. 22 demonstrated a significant association between p53 mutations and FOXF1 downregulation in breast and colorectal cancer cell lines. In the present study, a search of the Oncomine cancer profiling database revealed that FOXF1 mRNA was frequently underexpressed in primary tumor tissues with mutant p53 status as compared with those with wild-type status (Supplementary Figure S8) . This result supports a reduction of FOXF1 expression by p53 mutants (Supplementary Figure S9) . Taken together, FOXF1 expression may be decreased, at least partially, in a mutant p53-dependent manner in human cancers.
Among the p53 family members, TAp63g is the strongest transactivator of the FOXF1 gene. In humans, heterozygous microdeletion or point mutations in the FOXF1 gene have been found in patients with congenital alveolar capillary dysplasia, which presents with misaligned pulmonary veins (ACDMPV, MIM601089) and VACTERL (vertebral, anal, cardiac, tracheoesophageal, renal and limb) malformations (MIM192350). 56, 57 Of the p53 family members, p63 appears to have critical roles in normal development. 13, 58 Heterozygous germline mutations in the p63 gene have been identified in patients with five human syndromes characterized by limb malformations, craniofacial clefting and ectodermal dysplasia, 59 suggesting that p63 has a role in epidermal development partially by modulating FOXF1 expression during embryogenesis. However, given that p63 and p73 are not highly expressed in the mesenchymal cell (the normal site of FOXF1 expression), FOXF1 expression under normal physiological conditions might be mainly regulated by other transcription factors.
Lo et al. 21 demonstrated that FOXF1 suppresses the growth and tumorigenicity of breast cancer cells by inducing G1 cell cycle arrest and apoptosis. Moreover, our studies have elucidated the mechanisms underlying FOXF1-mediated tumor suppression. The EMT is a key step in cancer cell migration and invasion. TGF-b regulates the EMT and the metastasis-suppressor genes, including E-cadherin. 60 We demonstrate that TAp63g attenuates TGF-binduced E-cadherin downregulation in A549 cells. Furthermore, FOXF1-knockdown inhibited this effect, suggesting that TAp63g inhibits TGF-b-mediated E-cadherin downregulation by upregulating FOXF1 transcription. FOXF1 siRNA resulted in morphological alterations from an epithelial/cuboidal to a mesenchymal/fibroblastic shape, and the number of cell-cell contacts was reduced (Supplementary Figure S12) . Collectively, our findings indicate that p53-inducible FOXF1 can prevent cancer cell invasion and migration.
Recently, Nilsson et al. 61 showed overexpression of FOXF1 was associated with EMT phenotype and an invasive potential of breast cancer cells. They also found that FOXF1 enhanced tumorigenicity in nude mice, which is contradictory to our results. In our study, however, an analysis of the Oncomine database shows that FOXF1 levels are significantly reduced in multiple cancer types compared with the corresponding normal tissues (Supplementary Figure S6) . The use of PrognoScan indicated that a decreased expression of FOXF1 is associated with poor survival of several cancer patients (Supplementary Figure S7) . This result indicates that low expression of FOXF1 may serve as a poor prognostic factor for cancer patients. Additionally, a recent paper reports that cytoplasmic mislocalization of FOXF1 is associated with the malignancy and metastasis of colorectal cancers, 62 suggesting that FOXF1 might act as a transcription factor inhibiting tumor progression. Thus, FOXF1 may have cell type-or stage-specific functions during carcinogenesis. To establish the role of FOXF1 in cancer promotion and progression, it would be interesting to find out the relationship between EMT markers and FOXF1 expression in clinical cancer cases. In summary, our studies support a novel pathway in which the FOXF1 transcription factor regulates E-cadherin expression downstream of the p53 family members. Therefore, FOXF1 may serve as a novel molecular target for detecting and treating human cancers.
MATERIALS AND METHODS

Cell culture, plasmids and recombinant adenoviruses
The human osteosarcoma cell line Saos-2, lung cancer cell lines H1299 and A549, colorectal cancer cell lines SW480, DLD1, and HCT116, glioma cell line U373, oral cancer cell line Ca9-22 and embryonic kidney cell line HEK293 were obtained from either the American Type Culture Collection or the Japanese Collection of Research Bioresources (Osaka, Japan). The HCT116 cell line (p53 wild type) and its derivative cell line HCT116-p53 À / À lacking p53 were kindly provided by Dr Bert Vogelstein (Howard Hughes Medical Institute, Johns Hopkins University). p53 mutation status and expression of endogenous p63 and p73 isoforms in the cell lines are described in Supplementary Table S2 . The construction, purification and infection procedures of replication-deficient recombinant adenoviruses encoding the human p53 family proteins fused to an amino-terminal FLAG epitope (Ad-p53, Ad-p73a, Ad-p73b, Ad-p63g and Ad-p63a) or the bacterial lacZ gene (Ad-lacZ) were performed as previously described. 28, 40, 43 The relative efficiencies of the adenovirus infections p53-inducible FOXF1 inhibits cancer cell motility M Tamura et al into each cell line were determined by subjecting the cells infected with a control Ad-lacZ to X-gal staining and 90-100% of the cells were infected at an MOI of 25-100. To construct a FOXF1-expressing plasmid, the entire coding region of the human FOXF1 cDNA was inserted in-frame into the Halo-tagged vector pFN21A (Promega, Madison, WI, USA), producing an N-terminally Halo-tagged protein. The plasmid construct was sequenced and named pFN21A-FOXF1. Nutlin-3 was purchased from Sigma (St Louis, MO, USA), and TGF-b was purchased from R&D Systems (Minneapolis, MN, USA).
Real-time RT-PCR
Real-time RT-PCR was performed using TaqMan Gene Expression assays and a 7900HT real-time PCR system (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer's protocol. Relative gene expression levels were quantified using the DDC t method by normalizing transcript levels to the expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase. The data are shown as the mean ± standard errors of three independent experiments and were normalized to 1 based on their respective controls. The primer/probe sets used were as follows: FOXF1, Hs00230962_m1; E-cadherin, Hs01023894_m1; ZEB1, Hs00232783_m1; and GAPDH, Hs99999905_m1.
Immunoblot analysis
The primary antibodies that were used for immunoblotting are as follows: mouse anti-human p53 monoclonal antibody (mAb) (DO-1, Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse anti-human p73 mAb (ER-15 (Oncogene Research, Boston, MA, USA), mouse anti-human p63 mAb (4A4, Oncogene Research), rabbit anti-human FOXF1 polyclonal antibody (Aviva Systems Biology, San Diego, CA, USA), rabbit anti-human E-cadherin polyclonal antibody (H-108, Santa Cruz Biotechnology), rabbit anti-human ZEB1 polyclonal antibody (H-102, Santa Cruz Biotechnology), rabbit anti-human ZEB2 polyclonal antibody (H-260, Santa Cruz Biotechnology), rabbit anti-human N-cadherin polyclonal antibody (H-63, Santa Cruz Biotechnology), mouse anti-human p21 mAb (F-5, Santa Cruz Biotechnology), rabbit anti-human Halo Tag pAb (Promega) and mouse anti-b-actin mAb (C4, Chemicon, Billerica, MA, USA). The proteins were transferred onto Immobilon-P membranes (Millipore, Billerica, MA, USA) by electroblotting and an immunoblot analysis was performed as previously described. 28 The band intensity was quantified by using the ImageJ software program. Actin was included for normalization.
Chromatin immunoprecipitation assay
The ChIP assays were performed by using the ChIP Assay Kit (Upstate Biotechnology, Lake Placid, NY, USA) and antibodies against FLAG (M2, Sigma) or the Halo-tag (Promega). The cells (2 Â 10 6 ) were crosslinked with a 1% formaldehyde solution for 15 min at 37 1C. The cells were then lysed in 200 ml of SDS lysis buffer and were sonicated to generate 300-800 bp DNA fragments. After centrifugation, the cleared supernatant was diluted 10-fold with ChIP dilution buffer and was split into two equal portions; one portion was incubated with the appropriate antibody (5 mg) at 4 1C for 16 h and the other portion was used as a negative control (no antibody). Onefiftieth of the volume of the total extract was used for PCR amplification as the input control. Immune complexes were precipitated, washed and eluted, and DNA-protein crosslinks were reversed by heating at 65 1C for 4 h. The DNA fragments were purified and dissolved in 40 ml of TE. Recovered DNA was submitted for real-time PCR amplification using SYBR Green master mix and the 7900HT real-time PCR system (Applied Biosystems). Relative binding values (% of input) were calculated using the comparative cycle threshold method (2 À DDCt ). The sequences of each primer set are described in Supplementary Table S1 . The PCR products generated based on the ChIP template were directly sequenced to verify the identity of the amplified DNA.
Luciferase assay A 30-bp fragment of the p53 response element in the FOXF1 gene RE-FOXF1 (5 0 -AAGCTGGAGTGAGCTTGCCAGGGCCAGTCC-3 0 ) and its mutant form RE-FOXF1-mut (5 0 -AAGATGTAGTGAGATTTCCAGGGACAGTCC-3 0 ) and a 23-bp fragment of the FOXF1 response element in the CDH1 gene RE-CDH1 (5 0 -CACTAAATAAATAAATAGGAAAC-3 0 ) and its mutant form RE-CDH1-mut (5 0 -CACTAAAGCCCTCCCGCGGAAAC-3 0 ) were synthesized and inserted upstream of a minimal promoter in the pGL3-promoter vector (Promega). The resulting constructs were designated as pGL3-RE-FOXF1, pGL3-RE-FOXF1-mut, pGL3-RE-CDH1 and pGL3-RE-CDH-mut, respectively. Sub-confluent cells in 24-well plates were transfected with 2 ng of phRG-TK reporter (Renilla luciferase for internal control) and 100 ng of pGL3 reporter (Firefly luciferase as the experimental reporter) together with 100 ng of the appropriate expression vector by using the Lipofectamine 2000 reagent (Invitrogen). Twenty-four hours after transfection, the reporter gene activities were measured using the Dual-Luciferase Reporter Assay (Promega) according to the manufacturer's instructions. All of the experiments were performed in triplicate and were repeated at least three times.
Knockdown of FOXF1 by RNA interference
We designed a small interfering RNA (siRNA) vector against human FOXF1. The iLenti-siRNA vector (Applied Biological Materials, Richmond, BC, Canada) containing the H1 promoter was used to express the siRNA. The targeted sequence of the iLenti-si-FOXF1 vector was 5 0 -GCTCAACGAGTGCTTCAT-CAAGCTACCCA-3 0 . As a control, we used iLenti-siRNA vector without an insert (synthesized by Applied Biological Materials).
Cell invasion and migration assays
Cell invasion was analyzed using Matrigel invasion chambers (Becton Dickinson, Franklin Lakes, NJ, USA) following the manufacturer's protocol. Briefly, cells were washed twice with PBS and then were resuspended in DMEM at the appropriate density according to the specific experiment. Equal volumes (0.5 ml/chamber) of the cell suspensions were seeded in the Matrigel invasion chambers (Becton Dickinson), which were placed in 24-well culture plates containing 0.75 ml/well of culture medium supplemented with 10% fetal bovine serum. Cells that had invaded to the underside of the inserts after a 24-h incubation were stained and quantified by counting the cells from five microscopic fields. Cell invasiveness is expressed as the average number of invaded cells per microscopic field. The migration potential of the cells was analyzed using a modified Boyden chamber (tissue culture-treated, 6.5 mm in diameter, 8-mm pores; Becton Dickinson).
Statistical analysis
Experimental data were evaluated using Student's t-test with probability values of o0.05 considered significant.
